Skip to content

Homoeopathic medicines Aurum muriaticum natronatum and Fraxinus americana in reducing size of intramural uterine fibroid

Assessing the effectiveness of Homoeopathic medicines Aurum muriaticum natronatum and Fraxinus americana on regression of Intramural Fibroid A Comparative study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103749
Enrollment
60
Registered
2026-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N850- Endometrial hyperplasia

Interventions

Intervention1: Aurum muriaticum natronatum: To assess the effectiveness of Homoeopathic medicine Aurum muriaticum natronatum on regression of intramural uterine fibroid Control Intervention1: Fraxinus

Sponsors

Dr Aaliyafatima Maldar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who are willing to participate as volunteers in the study and sign the written informed consent. Newly diagnosed cases of Intramural uterine fibroid. Subjects between the age group of 25 to 45 years of age. Intramural uterine fibroid of size up to 5cm.

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers. Subjects with Hypothyroidism, Hyperthyroidism, Gross developmental defect or congenital abnormalities of the uterus, Pelvic inflammatory diseases, Diabetes mellitus and Hypertension. Fibroids with severe pain and bleeding with suspicion of acute torsion and other complications which needs immediate surgical intervention. Subjects who are taking medication from other system of medicine and subjects taking Homoeopathic medicine for the same complaint. Subjects with Hemoglobin less than 8g/dl

Design outcomes

Primary

MeasureTime frame
Complete regression of intramural uterine fibroid in USG abdomen and pelvis from baselineTimepoint: Complete regression of intramural uterine fibroid in USG abdomen and pelvis from baseline

Secondary

MeasureTime frame
Quality of lifeTimepoint: By the end of 6 months

Countries

India

Contacts

Public ContactAaliyafatima Maldar
renukasiddrampatil@gmail.com9606317210

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026